{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-240931","form_type":"8-K","ticker":"VRDN","cik":"0001590750","company_name":"Viridian Therapeutics, Inc.\\DE","filed_at":"2023-09-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.463200+00:00","generated_at":"2026-06-10T09:12:52.329904+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Viridian appoints Agios CMO Dr. Sarah Gheuens to Board of Directors","bullets":["Board expanded from 5 to 6 directors; Gheuens appointed Class I director until 2025 annual meeting.","Also appointed to Science and Technology Committee.","Compensation: $46,000 annual retainer and option for 40,000 shares vesting over 3 years.","Gheuens is CMO of Agios Pharmaceuticals (AGIO) and previously held roles at Biogen (BIIB).","No arrangements, family relationships, or material interests requiring disclosure."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-240931","json":"https://secwatch.observer/filing/0001193125-23-240931.json","markdown":"https://secwatch.observer/filing/0001193125-23-240931.md","text":"https://secwatch.observer/filing/0001193125-23-240931.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1590750/000119312523240931/0001193125-23-240931-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1590750/000119312523240931/d533906d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T09:12:52.329904+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"732842b345","claim":"Sarah Gheuens was appointed as Director at Viridian Therapeutics, Inc.\\DE.","evidence_excerpt":"Effective September 21, 2023, the Board of Directors (the “Board”) of Viridian Therapeutics, Inc. (the “Company”) increased the size of the Board from five to six directors and appointed a new director, Dr. Sarah Gheuens, to serve as a Class I director to hold office until the 2025 Annual Meeting of Stockholders and until her successor shall have been duly elected and qualified.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1590750/000119312523240931/0001193125-23-240931-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}